Kiadis Pharma Strengthens Management Team
05 Março 2019 - 1:45PM
Kiadis Pharma Strengthens Management Team
Dirk de Naeyer appointed Chief Operations Officer and
Martine Nolan as Head of Quality Assurance, effective March 1,
2019
Amsterdam, The
Netherlands, March 5, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or
the "Company") (Euronext Amsterdam and Brussels: KDS), a
clinical stage biopharmaceutical company, today announces senior
management appointments to further strengthen the Company as it
transitions into commercial stage. Dirk de Naeyer, who joined
Kiadis Pharma in October 2018 as Head of Supply Chain, moves to the
position of Chief Operations Officer, as a planned succession from
Jan Feijen. Martine Nolan joins as Head of Quality
Assurance. Both de Naeyer and Nolan will report to Kiadis' CEO
Arthur Lahr and be members of the Company's management team.
Arthur Lahr, CEO
of Kiadis Pharma, commented: "To start, I
would like to thank Jan for his contributions to Kiadis. He has
been instrumental in building the operations team with several
talented individuals, including Dirk, who has already made a
substantial contribution to our supply chain and development.
Martine's track record in commercial quality and manufacturing,
combined with Dirk's experience leading operations in both clinical
and commercial-stage biotechnology companies, will contribute to
our position as a leading fully-integrated biopharmaceutical
company. I am delighted to welcome Dirk and
Martine to their new positions - with their appointments, we have
strengthened and completed our leadership team, adding new
capabilities and expertise in anticipation of potential product
commercialization and scale up."
Prior to joining Kiadis, Mr. de
Naeyer was at Janssen Pharmaceuticals where he spent 14 years in
various leadership positions. Most recently, he was R&D and
Regulatory lead for the integration of Actelion into Janssen.
Before that, he was the head of the Janssen Global Clinical
Operations team and held supply chain and manufacturing leadership
positions in both commercial and clinical-stage small molecules,
biologics and stem cell platforms. Mr. de Naeyer joined Janssen
after five years at McKinsey. He holds a Masters in Engineering
from the KU Leuven, Belgium, and an MBA from the University of
Chicago.
Ms. Nolan brings over 20 years of
experience in the pharmaceutical sector to Kiadis which she joins
from Amgen where she served as Regional Head of Quality Operations,
leading a team of more than 200 employees at the Dublin, Ireland
and Breda, Netherlands sites. Prior to that Ms. Nolan served as
Executive Director for International Quality, Turkey, Middle East
& Africa where she had responsibility for quality of both
manufacturing and distribution activities. Before joining Amgen,
Ms. Nolan held several positions of increasing responsibility in
quality operations at Schering-Plough (Merck) in Ireland, Singapore
and US. Ms. Nolan holds a MSc in Cellular Physiology from
University College Cork and a BSc in Biochemistry from University
College Dublin.
For more
information, please contact:
Kiadis Pharma:
Amy Sullivan, SVP, Corporate Affairs
Tel. +1 508 479 3480
a.sullivan@kiadis.com |
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com
|
About Kiadis
Pharma
Kiadis Pharma is developing its lead product candidate, ATIR101,
for use in conjunction with haploidentical HSCT for adult blood
cancers to address key limitations of haploidentical HSCT, without
prophylactic immunosuppression and its associated morbidity and
mortality. Based on the positive results from the single dose Phase
II CR-AIR-007 study, the Company submitted a marketing
authorization application to the European Medicines Agency in April
2017 for approval of ATIR101 as an adjunctive treatment in
haploidentical HSCT for high risk adult hematological malignancies.
If the product is conditionally approved, Kiadis Pharma intends to
launch ATIR101 in selected countries in Europe through its own
commercial organization starting in the second half of 2019.
In December 2017, Kiadis Pharma
commenced an international, multicenter, randomized and controlled
Phase III clinical trial of ATIR101 against the Post-Transplant
Cyclophosphamide, or PTCy protocol, the main protocol used to
perform a haploidentical HSCT. The trial will be performed in 250
patients with acute leukemia and myelodysplastic syndrome at
approximately 50 sites in the United States, Canada, Europe and
certain additional countries. ATIR101 received regenerative
medicine advanced therapy designation from the FDA in September
2017, which provides benefits that are materially equivalent to a
breakthrough designation from the FDA. In addition, ATIR101 has
been granted multiple orphan Drug designations both in the European
Union and the United States.
The Company's shares are listed on
Euronext Amsterdam and Brussels under the ticker KDS.
Forward Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person's officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire